MX2012001461A - Preparacion farmaceutica, de administracion oral, que contiene insulina. - Google Patents

Preparacion farmaceutica, de administracion oral, que contiene insulina.

Info

Publication number
MX2012001461A
MX2012001461A MX2012001461A MX2012001461A MX2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
preparation containing
orally administerable
containing insulin
administerable pharmaceutical
Prior art date
Application number
MX2012001461A
Other languages
English (en)
Spanish (es)
Inventor
Szilvassy Dr Zoltan
Peitl Dr Barna
Nemeth Dr Jozsef
Original Assignee
Cera Med Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cera Med Kft filed Critical Cera Med Kft
Publication of MX2012001461A publication Critical patent/MX2012001461A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2012001461A 2009-08-03 2010-08-02 Preparacion farmaceutica, de administracion oral, que contiene insulina. MX2012001461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
MX2012001461A true MX2012001461A (es) 2012-05-22

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001461A MX2012001461A (es) 2009-08-03 2010-08-02 Preparacion farmaceutica, de administracion oral, que contiene insulina.

Country Status (15)

Country Link
US (1) US20120129769A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461820A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013501043A (cg-RX-API-DMAC7.html)
KR (1) KR20120088660A (cg-RX-API-DMAC7.html)
CN (1) CN102791282A (cg-RX-API-DMAC7.html)
AU (1) AU2010280418B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012002413A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769620A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0900482A2 (cg-RX-API-DMAC7.html)
IL (1) IL217856A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012001461A (cg-RX-API-DMAC7.html)
RU (1) RU2012109006A (cg-RX-API-DMAC7.html)
UA (1) UA106506C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011015984A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201519B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003824A1 (en) * 2011-06-29 2013-01-03 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3645736B1 (en) * 2017-06-28 2022-06-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for determining the risk to develop type 1 diabetes
KR20240171428A (ko) 2023-05-30 2024-12-09 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
DE68909135T2 (de) 1988-07-21 1994-04-07 Hoffmann La Roche Insulinzubereitung.
WO1993010767A1 (de) 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Perorale applikationsform für peptidarzneistoffe, insbesondere insulin
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
NZ500075A (en) 1997-04-02 2001-03-30 Purdue Research Foundation Method for the oral delivery of a protein encapsulated within a hydrogel matrix
AU1574900A (en) 1998-12-04 2000-06-26 Provalis (Uk) Limited Pharmaceutical compositions containing insulin
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
KR20060015472A (ko) 2003-03-04 2006-02-17 더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 약물전달 시스템 및 세포 치료법
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
JP5222727B2 (ja) * 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062408B (zh) * 2006-04-27 2010-12-08 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
JP2011504871A (ja) * 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー/エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment

Also Published As

Publication number Publication date
BR112012002413A2 (pt) 2016-03-01
US20120129769A1 (en) 2012-05-24
CA2769620A1 (en) 2011-02-10
WO2011015984A1 (en) 2011-02-10
AU2010280418B2 (en) 2015-04-09
AU2010280418A1 (en) 2012-03-22
JP2013501043A (ja) 2013-01-10
HUP0900482A2 (en) 2011-03-28
EP2461820A1 (en) 2012-06-13
ZA201201519B (en) 2013-05-29
RU2012109006A (ru) 2013-09-10
KR20120088660A (ko) 2012-08-08
IL217856A0 (en) 2012-03-29
CN102791282A (zh) 2012-11-21
HU0900482D0 (en) 2009-10-28
UA106506C2 (uk) 2014-09-10

Similar Documents

Publication Publication Date Title
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX336412B (es) Nuevos analogos de glucagon.
MY167234A (en) Novel glucagon analogues
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
NZ599774A (en) Melanocortin-1 receptor-specific cyclic peptides
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2013011175A (es) Analogos de glucagon novedosos.
PH12016500004A1 (en) Pcsk9 vaccine
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
EA201290549A1 (ru) Пептидный аналог оксинтомодулина
IN2012DN00639A (cg-RX-API-DMAC7.html)
EA201070046A1 (ru) Способ получения лекарственного средства, содержащего тадалафил
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
PH12013501902A1 (en) Infant formula for use in the prevention of cardiovascular diseases
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
AU2010286532A8 (en) Methods of treatment using anti-oxidized LDL antibodies
MX2012001461A (es) Preparacion farmaceutica, de administracion oral, que contiene insulina.
WO2013078376A3 (en) Isoxazole treatments for diabetes
WO2023285686A3 (en) Recombinant variants of r-spondin proteins and their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal